INTRAHEPATIC CHOLANGIOCARCINOMA
Clinical trials for INTRAHEPATIC CHOLANGIOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new INTRAHEPATIC CHOLANGIOCARCINOMA trials appear
Sign up with your email to follow new studies for INTRAHEPATIC CHOLANGIOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pump delivers chemo straight to liver tumors
Disease control OngoingThis study tests a combined pump and catheter system that delivers chemotherapy directly to the liver through the hepatic artery. It includes 100 adults with colorectal cancer or bile duct cancer that has spread to the liver. The goal is to see if the device is safe and works pro…
Matched conditions: INTRAHEPATIC CHOLANGIOCARCINOMA
Phase: NA • Sponsor: Ronald DeMatteo, M.D. • Aim: Disease control
Last updated May 17, 2026 02:15 UTC
-
Immunotherapy duo takes on 50+ rare cancers in major trial
Disease control OngoingThis phase 2 trial tests a combination of two immunotherapy drugs (nivolumab and ipilimumab) in over 800 people with more than 50 types of rare cancers. The goal is to see if this treatment can shrink tumors by helping the immune system attack cancer cells. The study is for patie…
Matched conditions: INTRAHEPATIC CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New drug combo shows promise for rare bile duct cancer
Disease control OngoingThis study tests a combination of two drugs, atezolizumab and derazantinib, in 27 adults with advanced bile duct cancer that has a specific FGFR2 gene change. The goal is to see if the treatment can shrink tumors and control the disease. Participants receive the drugs intravenous…
Matched conditions: INTRAHEPATIC CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
New combo therapy takes on hard-to-treat bile duct cancer
Disease control OngoingThis study tests whether adding immunotherapy drugs (durvalumab with or without tremelimumab) to a type of internal radiation therapy (Y-90 SIRT) can shrink tumors in people with advanced bile duct cancer that has not spread beyond the liver. About 50 adults whose cancer cannot b…
Matched conditions: INTRAHEPATIC CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
New drug cocktail aims to stop bile duct cancer from coming back
Disease control OngoingThis study tests whether giving a combination of immunotherapy (Toripalimab), a targeted drug (lenvatinib), and chemotherapy (GEMOX) before surgery can improve outcomes for people with a high-risk type of bile duct cancer. About 178 participants will be randomly assigned to recei…
Matched conditions: INTRAHEPATIC CHOLANGIOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated May 11, 2026 20:37 UTC
-
Liver tumor treatment study halted before it began
Knowledge-focused TerminatedThis study aimed to review past cases of patients with a rare liver cancer (intrahepatic cholangiocarcinoma) who were treated with tiny radioactive beads called radiospheres. The goal was to understand how well the treatment worked and what risks were involved. However, the study…
Matched conditions: INTRAHEPATIC CHOLANGIOCARCINOMA
Sponsor: Methodist Health System • Aim: Knowledge-focused
Last updated May 17, 2026 02:06 UTC